James Parslow
Chief Executive Officer at XENETIC BIOSCIENCES, INC.
Net worth: - $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Scott Maguire | M | 61 |
Lipoxen Technologies Ltd.
 Lipoxen Technologies Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1997, Lipoxen Technologies Ltd. is a British company that specializes in product development in the pharmaceutical industry. Part of Xenetic Biosciences, Inc., the company is based in London, UK.
Xenetic Biosciences (UK) Ltd.
 Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | 20 years |
| Colin William Hill | M | 79 |
Lipoxen Technologies Ltd.
Lipoxen Technologies Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1997, Lipoxen Technologies Ltd. is a British company that specializes in product development in the pharmaceutical industry. Part of Xenetic Biosciences, Inc., the company is based in London, UK.
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | 17 years |
| Adam Logal | M | 46 | 7 years | |
| Dmitriy Genkin | M | 56 | 5 years | |
| Roger Kornberg | M | 76 | 8 years | |
| Firdaus Jal Dastoor | M | 72 | 10 years | |
| Alexey Vinogradov | M | 54 | 5 years | |
| James Callaway | M | 68 | 7 years | |
| Grigory Borisenko | M | 55 | 5 years | |
| Moshe Mizrahy | M | 71 | - | |
| Sanjay Jain | M | - |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | 23 years |
| Brad Marcus | M | - |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | 17 years |
| Henry Hoppe | M | - |
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philip V. Adams | M | 66 | 12 years | |
| Peter Londa | M | 51 | 1 years | |
| Edward T. Libbey | M | 77 | 16 years | |
| Richard M. Domaleski | M | 54 | 16 years | |
| Jeffrey Eisenberg | M | 58 | 8 years | |
| Dave Laipple | M | - | - | |
| Curtis Lockshin | M | 64 | 10 years | |
| Patrick R. Bischoff | M | 55 | 9 years | |
| David B. Brewster | M | 52 | - | |
| Thad A. Wolfe | M | 81 | 8 years | |
| Ralph S. Sheridan | M | 73 | 2 years | |
| Sean S. Sweeney | M | 66 | 1 years | |
| Neil Moses | M | - | - | |
| John W. Wellard | M | 76 | 8 years | |
| Roman Sergeevich Knyazev | M | 44 | 5 years | |
| Dan May | M | - | - | |
| Tony Barnhart | M | - | - | |
| Darlene Deptula-Hicks | F | 66 | 3 years | |
| Martha Danly | M | 70 | - | |
| William Wiegler | M | - | - | |
| Edward Benz | M | 78 | 1 years | |
| Carolyn Oldenburg | F | - | - | |
| John C. Fox | M | 75 | 1 years | |
| Eric G. Alam | M | - | 2 years | |
| Timothy G. Healy | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 34 | 89.47% |
| United Kingdom | 5 | 13.16% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Parslow
- Personal Network
